Financials MannKind Corporation

Equities

MNKD

US56400P7069

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 16/01/2026 GMT			5-day change	1st Jan Change
5.210 ^USD	-6.63%		-10.94%	-8.11%

01-08	MannKind provides business updates and 2026 growth drivers	RE
12-23	MannKind Says FDA Approves Furoscix Autoinjector Use for Pediatric Patients With Fluid Retention	MT

Projected Income Statement: MannKind Corporation

Fiscal Period: December	2020	2021	2022	2023	2024	2025	2026	2027
Net sales ¹	65.14	75.44	99.77	199	285.5	345.6	436.4	504.6
Change	-	15.81%	32.25%	99.42%	43.5%	21.04%	26.28%	15.63%
EBITDA	-	-	-	-	-	-	-	-
Change	-	-	-	-	-	-	-	-
EBIT ¹	-34.68	-47.02	-64.11	8.678	72.59	74.93	70.28	102.2
Change	-	-35.59%	-36.34%	113.54%	736.45%	3.23%	-6.21%	45.41%
Interest Paid ¹	-9.471	-15.2	-24.77	-15.15	-37.98	-9.129	-12.16	-11.45
Earnings before Tax (EBT) ¹	-57.46	-80.93	-87.4	-10.38	30.52	41.53	26.88	56.94
Change	-	-40.84%	-8%	88.13%	394.09%	36.08%	-35.28%	111.84%
Net income ¹	-57.24	-80.93	-87.4	-11.94	27.59	35.63	19.93	76.9
Change	-	-41.38%	-8%	86.34%	331.09%	29.14%	-44.07%	285.89%
Announcement Date	25/02/21	24/02/22	23/02/23	27/02/24	26/02/25	-	-	-

¹USD in Million

Estimates

Fiscal Period: December	2020 Q4	2021 Q1	2021 Q2	2021 Q3	2021 Q4	2022 Q1	2022 Q2	2022 Q3	2022 Q4	2023 Q1	2023 Q2	2023 Q3	2023 Q4	2024 Q1	2024 Q2	2024 Q3	2024 Q4	2025 Q1	2025 Q2	2025 Q3	2025 Q4	2026 Q1	2026 Q2	2026 Q3	2026 Q4
Net sales ¹	18.44	17.44	23.28	22.21	12.52	11.99	18.89	32.82	36.06	40.63	48.61	51.25	58.47	66.26	72.39	70.08	76.78	78.35	76.53	82.13	99.85	110.6	115.6	126.8	137.6
Change	-	-5.46%	33.52%	-4.59%	-43.65%	-4.18%	57.56%	73.73%	9.85%	12.67%	19.65%	5.43%	14.09%	13.32%	9.24%	-3.19%	9.56%	2.06%	-2.33%	7.32%	21.58%	10.82%	4.43%	9.69%	8.6%
EBITDA	-	-	-9.332	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Change	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
EBIT ¹	-10.51	-6.191	-10.27	-6.59	-23.97	-21.26	-20.45	-9.61	-12.79	-5.998	1.721	5.097	7.858	16.72	16.61	12.76	26.5	22.29	5.299	18.9	16.6	-	-	-	-
Change	-	41.12%	-65.93%	35.85%	-263.7%	11.32%	3.77%	53.02%	-33.09%	53.1%	128.69%	196.17%	54.17%	112.8%	-0.67%	-23.18%	107.64%	-15.86%	-76.23%	256.6%	-12.12%	-	-	-	-
Charge d'intérêts ¹	-2.401	-6.452	-3.18	-2.803	-4.142	-5.119	-9.085	-5.278	-5.287	-5.21	-9.322	-5.274	-2.677	-9.262	-12.88	-8.36	-7.481	-10.63	-6.191	-7.334	-3.53	-	-	-	-
Earnings before Tax (EBT) ¹	-26.41	-12.92	-35.52	-4.426	-28.06	-26	-29.02	-14.43	-17.95	-9.795	-5.265	1.721	2.962	10.89	-1.691	12.87	8.445	13.62	0.94	7.781	8.03	-	-	-	-
Change	-	51.1%	-175.03%	87.54%	-534%	7.35%	-11.64%	50.27%	-24.36%	45.42%	46.25%	132.69%	72.11%	267.79%	-115.52%	861.09%	-34.38%	61.24%	-93.1%	727.77%	3.2%	-	-	-	-
Net income ¹	-26.41	-12.92	-35.52	-4.426	-28.06	-26	-29.02	-14.43	-17.95	-9.795	-5.265	1.721	1.401	10.63	-2.014	11.55	7.422	13.16	0.668	7.985	4.501	13.3	10.55	10.55	10
Change	-	51.1%	-175.03%	87.54%	-534%	7.35%	-11.64%	50.27%	-24.36%	45.42%	46.25%	132.69%	-18.59%	658.74%	-118.95%	673.49%	-35.74%	77.28%	-94.92%	1,095.36%	-43.63%	195.5%	-20.68%	0%	-5.21%
Announcement Date	25/02/21	12/05/21	11/08/21	09/11/21	24/02/22	05/05/22	09/08/22	08/11/22	23/02/23	09/05/23	07/08/23	07/11/23	27/02/24	08/05/24	07/08/24	07/11/24	26/02/25	08/05/25	06/08/25	05/11/25	-	-	-	-	-

¹USD in Million

Estimates

Forecast Balance Sheet: MannKind Corporation

Fiscal Period: December	2020	2021	2022	2023	2024	2025	2026	2027
Net Debt	-	-	-	-302	-	-	-	-
Change	-	-	-	-	-	-	-	-
Announcement Date	25/02/21	24/02/22	23/02/23	27/02/24	26/02/25	-	-	-

Estimates

Cash Flow Forecast: MannKind Corporation

Fiscal Period: December	2020	2021	2022	2023	2024	2025	2026	2027
CAPEX ¹	0.801	11.47	7.589	42.44	9.693	3.444	5.212	5.396
Change	-	1,331.46%	-33.81%	459.24%	-77.16%	-64.47%	51.34%	3.54%
Free Cash Flow (FCF) ¹	-	-	-	-8.347	32.82	74	79	138
Change	-	-	-	-	493.17%	125.49%	6.76%	74.68%
Announcement Date	25/02/21	24/02/22	23/02/23	27/02/24	26/02/25	-	-	-

¹USD in Million

Estimates

Forecast Financial Ratios: MannKind Corporation

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025	2026	2027
Profitability
EBITDA Margin (%)	-	-	-	-	-	-	-	-	-
EBIT Margin (%)	-	-53.24%	-62.33%	-64.26%	4.36%	25.42%	21.68%	16.1%	20.25%
EBT Margin (%)	-	-88.2%	-107.27%	-87.6%	-5.22%	10.69%	12.02%	6.16%	11.28%
Net margin (%)	-	-87.87%	-107.27%	-87.6%	-6%	9.66%	10.31%	4.57%	15.24%
FCF margin (%)	-	-	-	-	-4.2%	11.49%	21.41%	18.1%	27.35%
FCF / Net Income (%)	-	-	-	-	69.92%	118.96%	207.71%	396.44%	179.46%
Profitability
ROA	-28.86%	-15.31%	-15.49%	-13.98%	1.72%	9.88%	-	-	-
ROE	28.39%	30.86%	41.53%	38.01%	4.81%	-16.98%	-	-	-
Financial Health
Leverage (Debt/EBITDA)	-	-	-	-	-	-	-	-	-
Debt / Free cash flow	-	-	-	-	-	-	-	-	-
Capital Intensity
CAPEX / Current Assets (%)	-	1.23%	15.2%	7.61%	21.33%	3.4%	1%	1.19%	1.07%
CAPEX / EBITDA (%)	-	-	-	-	-	-	-	-	-
CAPEX / FCF (%)	-	-	-	-	-508.46%	29.54%	4.65%	6.6%	3.91%
Items per share
Cash flow per share ¹	-	-	-	-	-	-	-	-	-
Change	-	-	-	-	-	-	-	-	-
Dividend per Share ¹	-	-	-	-	-	-	-	-	-
Change	-	-	-	-	-	-	-	-	-
Book Value Per Share ¹	-	-	-	-	-	-	-	-	-
Change	-	-	-	-	-	-	-	-	-
EPS ¹	-	-0.26	-0.32	-0.34	-0.04	0.1	0.1129	0.075	0.2371
Change	-	-	-23.08%	-6.25%	88.24%	350%	12.86%	-33.55%	216.19%
Nbr of stocks (in thousands)	-	232,601	251,256	263,196	269,575	275,778	307,070	307,070	307,070
Announcement Date	-	25/02/21	24/02/22	23/02/23	27/02/24	26/02/25	-	-	-